Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus.
Jinghong LiQi WeiKaren C McCowenWei XiongJiao LiuWenlijun JiangRobert L ThomasMark HepokoskiMing HeJohn Y J ShyyAtul MalhotraNian XiongWillis X LiPublished in: Endocrinology, diabetes & metabolism (2021)
Our analyses suggest that inpatient use of metformin and acarbose together or alone during hospitalization should be studied in randomized trials.